H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Selecta Biosciences to $5 from $4 and keeps a Buy rating on the shares. The SEL-212 refractory gout pivotal trial program yielded positive data, the analyst tells investors in a research note. The firm believes SEL-212 "now appears well-situated to achieve substantive market uptake and has a high likelihood of regulatory approval."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SELB:
- Selecta Biosciences price target lowered to $4 from $5 at Mizuho
- Selecta Biosciences, Sobi announce DISSOLVE I and II meet primary endpoinr
- Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
- Selecta Biosciences risk/reward favorable into data, says Mizuho
- Selecta Biosciences price target lowered to $5 from $8 at Mizuho
